Revance Therapeutics (RVNC) Misses Q3 EPS by 10c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.37), $0.10 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $59.88 million versus the consensus estimate of $68.18 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
• Palo Alto Networks (PANW) PT Raised to $430 at Scotiabank
• Armstrong World Industries (AWI) Added to D.A. Davidson Best-of-Breed Bison List